drugset
drugset / Trial / NCT04814056

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NCT04814056 ↗

Phase 4 Unknown 15 enrolled Shanghai Chest Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, sing-arm, phase IV clinical study. The study is designed to evaluate the efficacy of Afatinib in treatment of NRG1-fused locally advanced/metastatic non-small cell lung cancer (NSCLC), and explore the clinical factors that may predict the effectiveness of treatment.

Timeline

Start
2021-06-01
Primary completion
2023-09-29
Completion
2024-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 30 mg Oral
Subject Afatinib Small molecule 40 mg Oral

Indications

non-small cell lung carcinoma